KRAS Inhibitor Daraxonrasib Shows Promise in Pancreatic Cancer
Revolution Medicines' daraxonrasib shows meaningful responses in KRAS-mutant pancreatic cancer in Phase 2 data, marking a breakthrough in a notoriously hard-to-treat disease.
Revolution Medicines
3 articles tagged "Revolution Medicines"
Revolution Medicines Raises $2B After Pancreatic Cancer Trial
Revolution Medicines closed a $2 billion raise after Phase 3 data showed daraxonrasib doubled median overall survival in advanced pancreatic cancer.
Pancreatic Cancer Pill Doubles Survival in New Trial
Revolution Medicines' daraxonrasib nearly doubled median survival in metastatic pancreatic cancer patients compared to chemotherapy, according to new data.